Achim A Jungbluth

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
    Dimitrios Balafoutas
    Department of Obstetrics and Gynecology, University Hospital Freiburg, Freiburg 79106, Germany
    BMC Cancer 13:271. 2013
  2. ncbi request reprint Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis
    A A Jungbluth
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Virchows Arch 434:429-35. 1999
  3. pmc Expression of cancer-testis (CT) antigens in placenta
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Immun 7:15. 2007
  4. pmc A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:639-44. 2003
  5. ncbi request reprint Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Diagn Pathol 25:120-5. 2008
  6. ncbi request reprint CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:839-45. 2002
  7. ncbi request reprint Expression of MAGE-antigens in normal tissues and cancer
    A A Jungbluth
    Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Int J Cancer 85:460-5. 2000
  8. ncbi request reprint Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 94:252-6. 2001
  9. ncbi request reprint Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 92:856-60. 2001
  10. pmc PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses
    Wilson A Silva
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 7:18. 2007

Detail Information

Publications87

  1. pmc Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
    Dimitrios Balafoutas
    Department of Obstetrics and Gynecology, University Hospital Freiburg, Freiburg 79106, Germany
    BMC Cancer 13:271. 2013
    ..Here we evaluated the expression patterns of CTAs and NY-BR-1 in breast cancer in correlation to clinico-pathological parameters in order to determine their possible impact as prognostic factors...
  2. ncbi request reprint Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis
    A A Jungbluth
    Ludwig Institute for Cancer Research at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Virchows Arch 434:429-35. 1999
    ..Our study demonstrates that A103 is a useful marker for the diagnosis of angiomyolipomas...
  3. pmc Expression of cancer-testis (CT) antigens in placenta
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Immun 7:15. 2007
    ..However, our data indicate that the various CT antigens have different functions during placental development...
  4. pmc A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:639-44. 2003
    ..Our study also indicates that DeltaEGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain...
  5. ncbi request reprint Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Diagn Pathol 25:120-5. 2008
    ..Among them, the most prominent is S100. Other reagents are D5 to MITF or PNL-2. The properties of these reagents are presented, and their usefulness as markers in the setting of metastatic melanoma in sentinel lymph nodes is discussed...
  6. ncbi request reprint CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:839-45. 2002
    ....
  7. ncbi request reprint Expression of MAGE-antigens in normal tissues and cancer
    A A Jungbluth
    Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Int J Cancer 85:460-5. 2000
    ..Tumor specimens showed great variability in the number of tumor cells showing 57B reactivity, with some tumors showing only small isolated clusters of positive cells to other tumors with uniform staining throughout the tumor...
  8. ncbi request reprint Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 94:252-6. 2001
    ..Our study shows that NY-ESO-1 is highly expressed in a homogeneous pattern in synovial sarcomas of both morphologic variants and both translocation types, making these tumors an attractive target for NY-ESO-1 antigen-based immunotherapy...
  9. ncbi request reprint Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 92:856-60. 2001
    ..There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression...
  10. pmc PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses
    Wilson A Silva
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 7:18. 2007
    ..We found by ELISA that PLAC1 is immunogenic in a subset of cancer patients and healthy women. Its physical and expression characteristics render it a potential target for both active and passive cancer immunotherapeutic strategies...
  11. pmc Immunomic analysis of human sarcoma
    Sang Yull Lee
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:2651-6. 2003
    ..NY-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunotherapies...
  12. ncbi request reprint NY-ESO-1: review of an immunogenic tumor antigen
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Adv Cancer Res 95:1-30. 2006
    ..An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here...
  13. ncbi request reprint MAGE antigen expression in monophasic and biphasic synovial sarcoma
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:225-9. 2002
    ..Our study demonstrates that MAGE is frequently and homogeneously expressed in synovial sarcomas of both morphological variants and both translocation types, making these tumors an attractive target for MAGE antigen-based immunotherapy...
  14. ncbi request reprint Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
    Immunol Rev 188:22-32. 2002
    ..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress...
  15. ncbi request reprint Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, and Department of Human Immunogenetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 172:3289-96. 2004
    ..This development provides the framework for further evaluating integrated immune responses in vaccine settings and for optimizing these responses for clinical benefit...
  16. ncbi request reprint Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma
    Lars Stelter
    Department of Nuclear Medicine, Human Oncology and Pathogenesis Program, and Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mol Imaging 12:67-73. 2013
    ..ADI treatment in melanoma xenografts has a tumor-reducing effect, which can be noninvasively imaged by quantifying tumor vascularization with FMT and IHC...
  17. doi request reprint Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6497-508. 2012
    ....
  18. pmc 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1878-85. 2011
    ..The primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients...
  19. ncbi request reprint Glycoprotein A34, a novel target for antibody-based cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immun 6:2. 2006
    ..The A34 antigen and monoclonal antibody may be of considerable value for immunotherapy of different types of cancer...
  20. ncbi request reprint Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck
    Manju L Prasad
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Head Neck 26:1053-7. 2004
    ..Primary mucosal melanomas of the head and neck (HNMM) are rare aggressive malignant tumors that are usually difficult to treat. CTAs may provide useful targets for therapy; however, their expression in HNMM is not known...
  21. pmc Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors
    Elsa F Velazquez
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
    Cancer Immun 7:11. 2007
    ..Our study suggests that patients with metastatic MM who express NY-ESO-1 may benefit from NY-ESO-1-based immunotherapy...
  22. ncbi request reprint Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:400-6. 2005
    ..Despite its reactivity with neutrophils, PNL2 appears to be a valuable supplementary reagent for the diagnosis of melanocytic tumors...
  23. pmc Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 33:1378-85. 2009
    ..It labels the majority of MCCs, but fails to react with pulmonary neuroendocrine carcinomas. We also found that neuroendocrine carcinomas of the skin arising in association with a squamous cell carcinoma seem to be independent of MCV...
  24. doi request reprint Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 188:3851-8. 2012
    ..Furthermore, targeted activation of tumor-recognizing CD4(+) T cells by vaccination or adoptive transfer could be a suitable strategy for enhancing the efficacy of tumor immunotherapy...
  25. ncbi request reprint Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6)
    Hearn J Cho
    Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Immun 6:12. 2006
    ..This is the first report of direct interaction between two CT antigens and may be pertinent in the light of the frequently coordinated expression of these proteins...
  26. pmc CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:20410-5. 2008
    ..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
  27. ncbi request reprint The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY, USA
    Blood 106:167-74. 2005
    ..Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma...
  28. pmc Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:8947-52. 2007
    ....
  29. ncbi request reprint SSX antigens as tumor vaccine targets in human sarcoma
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Cancer Immun 3:13. 2003
    ..The results of this study indicate that SSX antigens are relevant targets for the development of vaccine-based immunotherapy of sarcoma and encourage the start of vaccination trials using SSX-derived immunogens in sarcoma patients...
  30. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  31. pmc Immunologic correlates of the abscopal effect in a patient with melanoma
    Michael A Postow
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 366:925-31. 2012
    ..Funded by the National Institutes of Health and others.)...
  32. ncbi request reprint Clusterin expression in primary and metastatic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Cutan Pathol 33:619-23. 2006
    ..Our findings confirm the observation that clusterin can be expressed in melanoma, in particular primary desmoplastic melanoma. However, clusterin appears to be present only in a minority of melanomas...
  33. pmc CT-X antigen expression in human breast cancer
    Anita Grigoriadis
    Ludwig Institute for Cancer Research, 605 Third Avenue, New York, NY 10158, USA
    Proc Natl Acad Sci U S A 106:13493-8. 2009
    ..Because of the limited therapeutic options for ER-negative breast cancers, vaccines based on CT-X antigens might prove to be useful...
  34. ncbi request reprint Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray
    Dhananjay A Chitale
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:119-26. 2005
    ..CT antigens CT7, MAGE-A3 and MAGE-A4, but not NY-ESO-1, are expressed in high-grade endometrial carcinomas, and expression of MAGE-A4 is correlated with the presence of overexpressed p53...
  35. pmc Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:16723-8. 2011
    ....
  36. pmc MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin
    Tricia Nardiello
    New York University Cancer Institute, New York University School of Medicine, New York, New York, USA
    Clin Cancer Res 17:4309-19. 2011
    ..In this report, we examine the mechanistic role of MAGE-A in promoting survival of proliferating multiple myeloma cells...
  37. pmc Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas
    Beatrice W T Yin
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Immun 8:3. 2008
    ..Membrane transporter molecules, such as NaPi2b, represent a new family of potential cell surface targets for the immunotherapy of cancer with monoclonal antibodies...
  38. ncbi request reprint Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
    J Thorac Oncol 2:947-52. 2007
    ..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies...
  39. pmc Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Cancer Immun 10:1. 2010
    ..The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters...
  40. ncbi request reprint Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma
    Christina M Lohmann
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 26:1351-7. 2002
    ..Immunohistochemistry for S-100 protein, Melan-A/MART-1, or tyrosinase facilitates the recognition of melanocytes but does not distinguish between nodal nevus and metastatic melanoma...
  41. ncbi request reprint Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens
    Christina M Lohmann
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Melanoma Res 13:595-601. 2003
    ..In addition, they were all positive for CT antigens, with MA454 being the most commonly found, suggesting that CT antigens may be a promising immunotherapeutic target for oesophageal melanomas...
  42. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
    ..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
  43. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  44. ncbi request reprint Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Cancer Immun 3:9. 2003
    ..These data suggest that CT antigens may have important biological implications in malignant gammopathies and that CT-7 may be a suitable target for T cell-based and possibly antibody-mediated immunotherapy of myeloma...
  45. doi request reprint Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 37:413-20. 2013
    ..The high specificity and sensitivity of VE1 for the detection of mutant BRAF(V600E) suggests a valuable reagent for clinical purposes. Heterogeneity in BRAF expression may be relevant for treatment response to BRAF inhibitors...
  46. doi request reprint Histologic distinction between subungual lentigo and melanoma
    Bijal Amin
    Department of Pathology, The New York Presbyterian, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 32:835-43. 2008
    ....
  47. ncbi request reprint Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Cutan Pathol 31:274-80. 2004
    ..These findings document that diffuse melanosis may result from tumor lysis, with release of melanosomes into the bloodstream...
  48. ncbi request reprint Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  49. pmc T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine
    Moses K Donkor
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Immunity 35:123-34. 2011
    ..These findings reveal that T cell production of TGF-β1 is an essential requirement for tumors to evade immunosurveillance independent of TGF-β produced by tumors...
  50. doi request reprint Phase II study of extended-dose temozolomide in patients with melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 26:2299-304. 2008
    ..We hypothesized that expression of methylguanine methyltransferase (MGMT) in the tumor would correlate with drug resistance to TMZ...
  51. ncbi request reprint Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:4041-7. 2002
    ..In contrast, 9 of 9 colon cancer specimens showed overexpression of KNSL6 mRNA, ranging from 5 to 44 times the level detected in normal colon tissue, indicating that this antigen could also be a valuable therapeutic target...
  52. pmc Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    Eiichi Sato
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:18538-43. 2005
    ..We conclude that intraepithelial CD8+ TILs and a high CD8+/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer...
  53. doi request reprint WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
    Eleanor M Tyler
    Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
    Blood 121:308-17. 2013
    ....
  54. pmc Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
    Sylvia Adams
    New York University Cancer Institute, New York University School of Medicine, 462 First Avenue, New York, NY 10016, USA
    Cancer Immunol Immunother 60:999-1007. 2011
    ..The objective of this study was to examine the expression of CT antigens and their frequency in BRCA-associated breast cancers...
  55. pmc Evaluation of the clonal origin of multiple primary melanomas using molecular profiling
    Irene Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Invest Dermatol 129:1972-82. 2009
    ....
  56. doi request reprint Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes
    Peter A Savage
    Department of Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    Science 319:215-20. 2008
    ..Thus, the repertoire of antigens recognized by tumor-infiltrating T cells is broader than previously thought and includes peptides derived from ubiquitous self antigens that are normally sequestered from immune detection...
  57. ncbi request reprint Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Invest Dermatol 124:412-8. 2005
    ..Our results from gene expression profiling validate the distinction of DM from NDM. They also provide the opportunity to learn more about the biology of DM which had previously not yet been associated with this variant of melanoma...
  58. pmc A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Departments of Medicine, Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, 1 Gustave L Levy Place, P O Box 1208, New York, NY 10029 6574, USA
    Sarcoma 2013:168145. 2013
    ..Assessment of the ability of synovial sarcoma cell lines to present cancer-germ cell antigens may be useful in determining the reason for the observed lack of immunological or clinical activity...
  59. doi request reprint Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Patrick A Ott
    Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
    Invest New Drugs 31:425-34. 2013
    ..Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup...
  60. doi request reprint Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma
    Lars Stelter
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Nucl Med 53:281-6. 2012
    ..Without a clear biologic mandate, PET/CT with (18)F-FDG is currently used to monitor patients treated with ADI. However, it is unclear if it can be expected that (18)F-FDG responses will indicate (or predict) clinical benefit...
  61. pmc Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases
    Cristina R Antonescu
    Department of Patholog, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Mol Diagn 4:44-52. 2002
    ..These data confirm that EWS-ATF1 detection can be used as a highly sensitive diagnostic test for CCS and that CCS expresses the melanocyte-specific form of the MITF transcript, further supporting its genuine melanocytic differentiation...
  62. ncbi request reprint Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
    Hilary A Vaughan
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 10:8396-404. 2004
    ..This study evaluates typing strategies used to distinguish these two homologous but distinct antigens and to characterize and quantitate expression of each in clinical samples...
  63. ncbi request reprint Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer
    Yu Wang
    Typing and Monitoring Laboratory, Beijing Cancer Hospital, Beijing 100036, China
    Cancer Immun 4:11. 2004
    ..About 74% of the samples expressed at least one CT antigen, most frequently MAGE-3 (41.6%). NY-ESO-1 and MAGE-3 are thus potential targets for a multivalent CT antigen vaccine...
  64. ncbi request reprint NY-ESO-1 expression and immunogenicity in esophageal cancer
    Shoichiro Fujita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
    Clin Cancer Res 10:6551-8. 2004
    ..We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients...
  65. ncbi request reprint Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma
    Matthias Wolfl
    Children s Hospital, Department of Pediatric Hematology and Oncology, University of Cologne, Cologne, Germany
    Cancer Immunol Immunother 54:400-6. 2005
    ..Neuroblastoma cells are of neuroectodermal origin and express a number of cancer germline (CG) antigens. These CG antigens may represent a potential target for immunotherapy such as peptide-based vaccination strategies...
  66. ncbi request reprint NY-BR-1 is a differentiation antigen of the mammary gland
    Dirk Jager
    Medizinische Onkologie NCT, University Hospital Heidelberg, 69120 Heidelberg, Germany
    Appl Immunohistochem Mol Morphol 15:77-83. 2007
    ..These data indicate that NY-BR-1 is a differentiation antigen of the mammary gland that could be useful for diagnosis and/or immunotherapy of breast carcinomas...
  67. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  68. ncbi request reprint Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene
    Terrance G Johns
    Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne, Australia
    Int J Cancer 98:398-408. 2002
    ..Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface...
  69. ncbi request reprint NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
    Yurika Sugita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita City, Osaka 565 0871, Japan
    Cancer Res 64:2199-204. 2004
    ....
  70. pmc T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein
    Akiko Uenaka
    Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata cho, Okayama, Japan
    Cancer Immun 7:9. 2007
    ..The use of whole protein, containing multiple CD4 and CD8 epitopes, may be beneficial for cancer vaccines to prevent tumors from evading the immune response...
  71. ncbi request reprint SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer
    Jonathan Tammela
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Immun 4:10. 2004
    ..The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted...
  72. ncbi request reprint Tumor antigen expression in melanoma varies according to antigen and stage
    Catherine Barrow
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 12:764-71. 2006
    ..Obtaining a detailed understanding of antigen expression in primary and metastatic melanoma is essential if these molecules are to be useful targets for immunotherapy of melanoma...
  73. ncbi request reprint Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
    Rushika M Perera
    Ludwig Institute for Cancer Research, Melbourne Branch, Tumor Targeting Program, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Cancer Res 11:6390-9. 2005
    ..Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic...
  74. ncbi request reprint NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 63:6076-83. 2003
    ..These findings indicate that NY-ESO-1 and LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC...
  75. ncbi request reprint NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
    Jean Philippe Theurillat
    Institute for Surgical Pathology, Department of Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
    Cancer Immunol Immunother 56:1723-31. 2007
    ....
  76. pmc A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
    Andrew M Scott
    Ludwig Institute for Cancer Research, 143 165 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 104:4071-6. 2007
    ..These in vitro and in vivo characteristics of ch806 distinguish it from all other antibodies targeting EGFR...
  77. ncbi request reprint The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer
    Inka Seil
    Georg Speyer Haus, Institute for Biomedical Research, Frankfurt, Germany
    Int J Cancer 120:2635-42. 2007
    ....
  78. pmc Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:346-52. 2007
    ..Taken together, these data support the hypothesis that mAb806 may lead to significant advancements in the treatment of the population of NSCLC patients with these 2 classes of EGFR mutations...
  79. pmc Cancer-testis (CT) antigen expression in medulloblastoma
    Sueli M Oba-Shinjo
    Department of Neurology, School of Medicine, University of Sao Paulo, Av Dr Arnaldo, 455, Room 4110, Sao Paulo, Brazil
    Cancer Immun 8:7. 2008
    ....
  80. pmc Cancer/testis (CT) antigens are expressed in fetal ovary
    Peter T Nelson
    Sanders Brown Center on Aging and Dept of Pathology, University of Kentucky, Lexington, KY, USA
    Cancer Immun 7:1. 2007
    ..We conclude that CT antigens are regularly expressed in fetal ovarian germ cells and might play an important role in male and female germ cell biology...
  81. ncbi request reprint A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma
    Junichi Sakamoto
    Department of Epidemiological and Clinical Research Information Management, Kyoto University, Kyoto 606 8501, Japan
    Cancer Sci 97:1248-54. 2006
    ....
  82. doi request reprint Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence
    Daniel Perez
    Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 123:1551-5. 2008
    ..The CTA staining could add information to the individual patient prognosis and represent an interesting target for future treatment strategies...
  83. ncbi request reprint Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
    Djordje Atanackovic
    Department of Oncology Hematology, Institute for Biochemistry and Molecular Biology, University Medical Center Hamburg Eppendorf, Germany
    Blood 109:1103-12. 2007
    ..Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM...
  84. doi request reprint Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination
    Hisashi Wada
    Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
    Int J Cancer 123:2362-9. 2008
    ..The induction of NY-ESO-1 immunity and some preferable clinical outcomes were observed in esophageal cancer patients by vaccination with NY-ESO-1. However, the tumors grew eventually by various mechanisms after vaccination...
  85. ncbi request reprint Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases
    Zsuzsanna Varga
    Institute of Surgical Pathology, Department Pathology, University Hospital of Zurich, Zurich, Switzerland
    Clin Cancer Res 12:2745-51. 2006
    ..However, current data are based on RT-PCR analysis and nothing is known about the presence of NY-BR-1 on a protein level. We previously generated a monoclonal antibody to NY-BR-1 to study the protein expression of NY-BR-1...
  86. ncbi request reprint Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2
    Ran Zhuang
    Department of Immunology, Fourth Military Medical University, Xi an 710032, PR China
    Cancer Immun 6:7. 2006
    ..In tumors, we analyzed a limited number of cases displaying the typical heterogeneous CT expression pattern. Interestingly, immunoreactivity was seen solely in the nucleus: No staining was seen in the cytoplasm of tumor cells...
  87. pmc Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
    Terrance G Johns
    Ludwig Institute for Cancer Research, Austin Hospital, Studley Road, Heidelberg 3084, Australia
    Proc Natl Acad Sci U S A 100:15871-6. 2003
    ..These results establish the antitumor efficacy of the EGFR inhibitor AG1478 and provide a rationale for its clinical evaluation in combination with both chemotherapy and other EGFR therapeutics...